Study of the cytotoxicity and antioxidant capacity of N/OFQ(1-13)NH 2 and its structural analogues

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1163-1172

  Kirkova, Margarita ^a   Zamfirova, Rositsa ^a   Leśkiewicz, Monika ^b   Kubera, Marta ^b   Lasoń, Władysław ^b   Todorov, Simeon ^a  

^a BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Glutathione; antioxidant enzyme activities; Lipid peroxidation; SH SY5Y neuroblastoma cells

Indexed keywords

ANTIOXIDANT; FREE RADICAL; HYDROGEN PEROXIDE; NOCICEPTIN DERIVATIVE; NOCICEPTIN[1-13]AMINE; OPIATE RECEPTOR; OXYGEN RADICAL; STAUROSPORINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN TISSUE; CELL DAMAGE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; IN VITRO STUDY; LIVER; MALE; NEUROBLASTOMA CELL; NONHUMAN; RAT; RECEPTOR AFFINITY;

EID: 76049101063     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70179-3     Document Type: Article

References (44)

1. Armstead WM: NOC/oFQ PKC-dependent superoxide generation contributes to hypoxic-ischemic impairment of NMDA cerebrovasodilation. Am J Physiol Heart Circ Physiol, 2000, 279, H2678-H2684.
2. Armstead WM: Role of altered cyclooxygenase metabolism in impaired cerebrovasodilation to nociceptin/orphanin FQ following brain injury. Brain Res Bull, 2000, 53, 807-812.
3. Beauchamp C, Fridovich I: Superoxide dismutase: improved assays and assay applicable to acrylamide gels. Anal Biochem, 1971, 44, 276-287.
4. Buzas B: Regulation of nociceptin/orphanin FQ gene expression in astrocytes by ceramide. Neuroreport, 2002, 13, 1707-1710.
5. Calo G, Guerrini R, Rizzi A, Salvadori S, Regoli D: Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol, 2000, 129, 1261-1283.
6. 2+ in the SH-SY5Y human neuroblastoma cell-line. Br J Pharmacol, 1996, 118, 205-207.
7. Carra G, Rizzi A, Guerrini R, Barnes TA, McDonald J, Hebbes CP, Mela F et al: [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/ orphanin FQ receptor. J Pharmacol Exp Ther, 2005, 312, 1114-1123.
8. Cartier P, Leroux JP, Marchand JC: Techniques de dosage des enzymes glycocytiques tissulaires. Ann Biol Clin, 1967, 25, 109-136.
9. Champion HC, Bivalacqua TJ, Zadina JE, Kastin AJ, Hyman AL, Kadowitz PJ: Role of nitric oxide in mediating vasodilator responses to opioid peptides in the rat. Clin Exp Pharmacol Physiol, 2002, 29, 229-232.
10. Chen Y, Sommer C: Nociceptin and its receptor in rat dorsal root ganglion neurons in neuropathic and inflammatory pain models: implications on pain processing. J Peripher Nerv Syst, 2006, 11, 232-240.
11. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H, Iwabe N, Miyata T et al.: cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett, 1994, 343, 42-46.
12. Guerrini R, Rizzi D, Zucchini M, Tomatis R, Regoli D, Calo G, Salvadori S: Nociceptin/Orphanin FQ(1-13) NH2 analogues modified in the Phe1-Gly2 peptide bond. Bioorg Med Chem Lett, 2003, 13, 365-368.
13. Gündüz O, Rizzi A, Baldisserotto A, Guerrini R, Spagnolo B, Gavioli EC, Kocsis L et al: In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol. Eur J Pharmacol, 2006, 539, 39-48.
14. Gunzler WA, Vergin H, Muller I, Flohe L: Glutathione peroxidase VI: the reaction of glutathione peroxidase with various hydroperoxides (German). HoppeSeylers Z Physiol Chem, 1972, 353, 1001-1004.
15. Halliwell B, Grootveld M, Gutteridge J: Methods for the measurement of hydroxyl radicals in biomedical systems: deoxyribose degradation and aromatic hydroxylation. Methods Biochem Anal, 1988, 33, 59-90.
16. Hirsch EC: Does oxidative stress participate in nerve cell death in Parkinson's disease? Eur Neurol, 1993, 33, Suppl 1, 52-59.
17. Hunter F, Gebinski J, Hoffstein P, Weinstein J, Scott A: Swelling and lysis of rat liver mitochondria induced by ferrous ions. J Biol Chem, 1963, 238, 828-835.
18. Ito S, Okuda-Ashitaka E, Minani T: Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res, 2001, 41, 299-332.
19. Jantas D, Pytel M, Mozrzymas JW, Leśkiewicz M, Regulska M, Antkiewicz-Michaluk L, Lasoń W: The attenuating effect of memantine on staurosporine-, salsolinol-and doxorubicin-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int, 2008, 52, 864-877.
20. Kruman I, Guo Q, Mattson MP: Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J Neurosci Res, 1998, 51, 293-308.
21. Kubera M, Holan V, Basta-Kaim A, Roman A, Borycz J, Shani J: Effect of desipramine on immunological parameters in mice, and their reversal by stress. Int J Immunopharmacol, 1998, 20, 429-438.
22. Kulkarni M, Armstead WM: Superoxide generation links nociceptin/orphanin FQ (NOC/oFQ) release to impaired N-methyl-D-aspartate cerebrovasodilation after brain injury. Stroke, 2000, 31, 1990-1996.
23. Leśkiewicz M, Regulska M, Budziszewska B, Jantas D, Jaworska-Feil L, Basta-Kaim A, Kubera M et al: Effects of neurosteroids on hydrogen peroxide- and staurosporine-induced damage of human neuroblastoma SH-SY5Y cells. J Neurosci Res, 2008, 86, 1361-1370.
24. Leśkiewicz M, Regulska M, Budziszewska B, Jantas D, Jaworska-Feil L, Basta-Kaim A, Kubera M, Lasoń W: Neurosteroids enhance the viability of staurosporine and doxorubicin treated differentiated human neuroblastoma SH-SY5Y cells. Pharmacol Rep, 2008, 60, 685-691.
25. Lowry OH, Rosenbrough NJ, Farr AL, Randal RJ: Protein measurement with the Folin phenol reagent. J Biol Chem, 1951, 193, 265-278.
26. Mabuchi T, Matsumura S, Okuda-Ashitaka E, Kitano T, Kojima H, Nagano T, Minami T, Ito S: Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production. Eur J Neurosci, 2003, 17, 1384-1392.
27. Marti M, Trapella C, Viaro R, Morari M: The nociceptin/ orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci, 2007, 27, 1297-1307.
28. Meunier JC, Mollereau C, Toll L, Suandeau C, Moisdan C, Alvinerie P, Butour JL et al.: Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 1995, 377, 532-535.
29. Mogil JS, Grisel JE, Reinscheid RK, Civelli O, Belknap JK, Grandy DK: Orphanin FQ is a functional anti-opioid peptide. Neurocsience, 1996, 75, 333-337.
30. Mollereau C, Parmentier M, Mailleux P, Burour JJ, Moisdan C, Chalon P, Caput D et al.: ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett, 1994, 341, 33-38.
31. 2 analogues modified in 9 and/or 13 position". Bioorg Med Chem Lett, 2006, 16, 4071-4074.
32. Peng YL, Chang M, Dong SL, Li W, Han RW, Fu GX, Chen Q, Wang R: Novel potent agonist [(pF)Phe4,Aib7, Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15] N/OFQ-NH2 of nociceptin/orphanin FQ receptor. Regul Pept, 2006, 134, 75-81.
33. Pinto RE, Bartly W: The effect of age and sex on glutathione reductase and glutathione peroxidase activities and on aerobic glutathione oxidation in rat liver homogenates. Biochem J, 1969, 112, 109-115.
34. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grady DK et al.: Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science, 1995, 270, 792-794.
35. Rosenberger J, Petrovics G, Buzas B: Oxidative stress induces proorphanin FQ and proenkephalin gene expression in astrocytes through p38- and ERK-MAP kinases and NF-κB. J Neurochem, 2001, 79, 35-44.
36. Ruegg UT, Burgess GM: Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci, 1989, 10, 218-220.
37. Seleznev K, Zhao Ch, Zhang XH, Song K, Ma ZA: Calcium-independent phospholipase A2 localizes in and protects mitochondria during apoptotic induction by staurosporine. J Biol Chem, 2006, 281, 22275-22288.
38. Serra JA, Dominguez RO, de Lustig ES, Guareschi EM, Famulari AL, Bartolome EL, Marschoff ER: Parkinson's disease is associated with oxidative stress: comparision of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J Neural Transm, 2001, 108, 1135-1148.
39. Sudha K, Rao AV, Rao S, Rao A: Free radical toxicity and antioxidants in Parkinson's disease. Neurology India, 2003, 51, 60-62.
40. Thakker DR, Standifer KM: Orphanin FQ/nociceptin blocks chronic morphine-induced tyrosine hydroxylase upregulation. Mol Brain Res, 2002, 105, 38-46.
41. Tietze F: Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem, 1969, 27, 502-522.
42. Yang CB, Tsai PJ, Chou ST, Niu YL, Lai JS, Kuo JS: The roles of reactive oxygen species and endogenous opioid peptides in ischemia-induced arrhythmia of isolated rat hearts. Free Radic Biol Med, 1995, 18, 593-598.
43. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI et al: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 1997, 275, 1129-1132.
44. Yin DL, Ren XH, Zheng ZL, Pu L, Jiang LZ, Ma L, Pei G: Etorphine inhibits cell growth and induces apoptosis in SK-N-SH cells: involvement of pertussis toxin-sensitive G proteins. Neurosci Res, 1997, 29, 121-127.